Multidrug Resistant Bacteria Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The multidrug resistant bacteria market size has grown strongly in recent years. It will grow from $12.61 billion in 2024 to $13.4 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to antibiotic resistance crisis, advancements in drug discovery, regulatory incentives, public health initiatives.

The multidrug resistant bacteria market size is expected to see strong growth in the next few years. It will grow to $17.5 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to antibiotic stewardship programs, global spread of resistance, phage therapy and alternative treatments, public and private investment. Major trends in the forecast period include precision medicine for infectious diseases, combination therapies, continuous surveillance and monitoring, global collaboration.

The growing prevalence of infectious diseases is expected to drive the expansion of the multidrug-resistant bacteria market. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites. Multidrug-resistant bacteria are particularly linked to infectious diseases due to their ability to cause infections that are challenging to treat with standard antibiotics. These bacteria have developed resistance to multiple antibiotics, making them less responsive to the medications typically used to treat bacterial infections. For example, in November 2023, the Centers for Disease Control and Prevention (CDC), a U.S.-based national public health agency, reported that the number of tuberculosis cases in the USA increased from 8,320 in 2022 to 9,615 in 2023, reflecting an increase of 1,295 cases. Therefore, the rising prevalence of infectious diseases is expected to fuel the growth of the multidrug-resistant bacteria market.

Major companies operating in the multidrug-resistant bacteria market are placing a strong emphasis on the development of innovative drugs and securing approvals to address the needs of a new segment of consumers. The approval of drugs designed to combat multidrug-resistant bacteria is crucial in the ongoing fight against antibiotic resistance. For example, in May 2023, Entasis Therapeutics Inc., a US-based biotech company, achieved approval from the Food and Drug Administration (FDA) for Xacduor, a combination antibiotic formulated to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VAP) caused by acinetobacter baumannii, a particularly challenging pathogen to treat. Xacduor consists of a combination of ceftolozane and tedizolid phosphate. Ceftolozane is a cephalosporin antibiotic, while tedizolid phosphate belongs to the oxazolidinone class of antibiotics. This approval provides a new treatment option for patients infected with Acinetobacter baumannii who have not responded to other therapies. It can be administered via injection and combines the antibiotic beta-lactam sulbactam with the broad-spectrum beta-lactamase inhibitor durlobactam, reducing acinetobacter resistance and enabling the antibiotic to effectively combat the infection.

In July 2022, Innoviva Inc., a US-based pharmaceutical company, acquired Entasis Therapeutics Inc. for an undisclosed amount. This strategic acquisition expands Innoviva's portfolio, encompassing potential first- and best-in-class medications for the treatment of multidrug-resistant gram-negative bacteria, including the lead asset SUL-DUR. Entasis Therapeutics Inc. is a US-based biotech company specializing in the development of antibacterial therapeutics aimed at addressing serious infections caused by multidrug-resistant bacteria.

Major players in the multidrug resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Lupin Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.

North America was the largest region in the multidrug-resistant bacteria market in 2024. The regions covered in multidrug-resistant bacteria report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the multidrug-resistant bacteria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multidrug-resistant bacteria market consists of revenues earned by entities by providing services such as infection diagnosis and combination therapy, surgery and antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The multidrug-resistant bacteria market also consists of sales of colistin, polymyxins, aminoglycosides, antibiotic synergy kits, monoclonal antibodies and vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Multidrug-resistant bacteria are strains of bacteria that have developed resistance to multiple classes of antibiotics, rendering them no longer susceptible to the effects of several different antibiotics that are typically effective in treating bacterial infections. These resilient bacteria are often found in hospital and medical care settings, where antibiotics are sometimes overused or used unnecessarily.

Various diseases are caused by multidrug-resistant bacteria, including urinary tract infections, intra-abdominal infections, bloodstream infections, Clostridium difficile infections, acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia, among others. Urinary tract infections, for example, can affect different parts of the urinary system, such as the kidneys, bladder, and ureters. The treatment of these diseases involves the use of various drugs, including oxyazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination therapies, and more, administered through oral, parenteral, and other routes. These treatments are provided to patients in various healthcare settings, including hospitals, specialty clinics, homecare, and others.

The multidrug-resistant bacteria market research report is one of a series of new reports that provides multidrug-resistant bacteria market statistics, including multidrug-resistant bacteria industry global market size, regional shares, competitors with a multidrug-resistant bacteria market share, detailed multidrug-resistant bacteria market segments, market trends and opportunities and any further data you may need to thrive in the multidrug-resistant bacteria industry. This multidrug-resistant bacteria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.